151 related articles for article (PubMed ID: 35589344)
1. SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: the COmmunity Cohort Study protocol.
Bachelet VC; Silva-Ayarza I; Lizana FJ; Gomolán P; Silva-Villalobos D; Navarrete MS
BMJ Open; 2022 May; 12(5):e061345. PubMed ID: 35589344
[TBL] [Abstract][Full Text] [Related]
2. University population-based prospective cohort study of SARS-CoV-2 infection and immunity (SARSSURV-ULiège): a study protocol.
Donneau AF; Guillaume M; Bours V; Dandoy M; Darcis G; Desmecht D; Diep AN; Fievez L; Garigliany MM; Gillain N; Husson E; Michel F; Moutschen M; Paridans M; Benoît P; Sabatel C; Saegerman C; Tytgat A; Gillet L; Bureau F
BMJ Open; 2022 Jan; 12(1):e055721. PubMed ID: 35078848
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
4. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium during 1 year of the COVID-19 epidemic: prospective cohort study protocol.
Adriaenssens N; Scholtes B; Bruyndonckx R; Verbakel JY; De Sutter A; Heytens S; Van den Bruel A; Desombere I; Van Damme P; Goossens H; Buret L; Duysburgh E; Coenen S
BMJ Open; 2022 Jan; 12(1):e054688. PubMed ID: 35105642
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
8. Specchio-COVID19 cohort study: a longitudinal follow-up of SARS-CoV-2 serosurvey participants in the canton of Geneva, Switzerland.
Baysson H; Pennachio F; Wisniak A; Zabella ME; Pullen N; Collombet P; Lorthe E; Joost S; Balavoine JF; Bachmann D; Azman A; Pittet D; Chappuis F; Kherad O; Kaiser L; Guessous I; Stringhini S;
BMJ Open; 2022 Jan; 12(1):e055515. PubMed ID: 35105645
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: The COmmunity Cohort Study.
Bachelet VC; Silva-Ayarza I; Navarrete MS
Medwave; 2023 Dec; 23(11):e2787. PubMed ID: 38117982
[TBL] [Abstract][Full Text] [Related]
10. The dynamics and determinants of specific systemic and mucosal antibody responses to SARS-CoV-2 in three adult cohorts in the Ecuadorian Andes: a study protocol.
Leon-Rojas JE; Veloz T; Teran J; Perez M; Arias-Erazo F; Villacis L; Velez J; Recalde R; Jiménez P; Martin M; Chis Ster I; Cooper P; Romero N
F1000Res; 2022; 11():1392. PubMed ID: 38434000
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of SARS-CoV-2 seroprevalence among primary healthcare patients in the Barcelona Metropolitan Area: the SeroCAP sentinel network protocol.
Sentís A; Torán P; Esperalba J; Agustí C; Ángel M; Fernández MG; Dopico E; Salvador-González B; González MV; Bordas A; Antón A; Violan C; Montoro-Fernández M; Aceiton J; Egea-Cortés L; Alonso L; Dacosta-Aguayo R; Calatayud L; Lejardi Y; Mendioroz J; Basora J; Reyes-Urueña J; Casabona J
BMJ Open; 2022 Feb; 12(2):e053237. PubMed ID: 35140153
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
13. Early warning and rapid public health response to prevent COVID-19 outbreaks in long-term care facilities (LTCF) by monitoring SARS-CoV-2 RNA in LTCF site-specific sewage samples and assessment of antibodies response in this population: prospective study protocol.
Lee BE; Sikora C; Faulder D; Risling E; Little LA; Qiu Y; Gao T; Bulat R; Craik S; Hrudey SE; Ohinmaa A; Estabrooks CA; Gingras AC; Charlton C; Kim J; Wood H; Robinson A; Kanji JN; Zelyas N; O'Brien SF; Drews S; Pang XL
BMJ Open; 2021 Aug; 11(8):e052282. PubMed ID: 34417219
[TBL] [Abstract][Full Text] [Related]
14. Protocol of the Luebeck longitudinal investigation of SARS-CoV-2 infection (ELISA) study - a prospective population-based cohort study.
Balck A; Föh B; Borsche M; Rahmöller J; Vollstedt EJ; Waldeck F; Käding N; Twesten C; Mischnik A; Gillessen-Kaesbach G; Ehlers M; Sina C; Taube S; Busch H; Rupp J; Katalinic A; Klein C
BMC Public Health; 2022 Jul; 22(1):1305. PubMed ID: 35799167
[TBL] [Abstract][Full Text] [Related]
15. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
[TBL] [Abstract][Full Text] [Related]
16. Risk of COVID-19 re-infection and its predictors (CORES): protocol for a community-based longitudinal cohort study in Vellore, India.
Madhavan R; Paul JS; Babji S; Kumar D; Prabhu SB; Pulleri HK; Annadorai R; Gowda SR; John J; Kang G
BMJ Open; 2022 May; 12(5):e059869. PubMed ID: 35613771
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal assessment of SARS-CoV-2 IgG seroconversionamong front-line healthcare workers during the first wave of the Covid-19 pandemic at a tertiary-care hospital in Chile.
Iruretagoyena M; Vial MR; Spencer-Sandino M; Gaete P; Peters A; Delgado I; Perez I; Calderon C; Porte L; Legarraga P; Anderson A; Aguilera X; Vial P; Weitzel T; Munita JM
BMC Infect Dis; 2021 May; 21(1):478. PubMed ID: 34039287
[TBL] [Abstract][Full Text] [Related]
18. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
[TBL] [Abstract][Full Text] [Related]
20. High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort.
Lalwani P; Araujo-Castillo RV; Ganoza CA; Salgado BB; Pereira Filho IV; da Silva DSS; de Morais TBDN; Jordão MF; Ortiz JV; Barbosa ARC; Sobrinho WBS; Cordeiro IB; de Souza Neto JN; de Assunção EN; da Costa CF; de Souza PE; de Albuquerque BC; Astofi-Filho S; ; Lalwani JDB
Lancet Glob Health; 2021 Nov; 9(11):e1508-e1516. PubMed ID: 34678195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
